BFM
BIOR

Boothbay Fund Management’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Boothbay Fund Management’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-132
Closed -$38K – 2846
2022
Q1 		$38K Buy
132
+10
+8% +$3.79K ﹤0.01% 2202
2021
Q4 		$64K Buy
+122
New +$87.6K ﹤0.01% 1758
2021
Q3 		– Sell
-40
Closed -$36K – 2314
2021
Q2 		$36K Buy
+40
New +$30.6K ﹤0.01% 1790

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Boothbay Fund Management's BIOR Position: Q2 2022 in Review

Boothbay Fund Management sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q2 2022, closing a stake of 132 shares — an estimated $38K sold.

Boothbay Fund Management first reported a position in BIOR in Q2 2021 and held it in 3 quarters. The position peaked at $64K in Q4 2021. 46 funds tracked by Wall St. Rank hold BIOR as of Q2 2022.

  • Boothbay Fund Management reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 132 Biora Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $38K.
  • Boothbay Fund Management first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Boothbay Fund Management's Biora Therapeutics, Inc. Common Stock position peaked at $64K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.